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Abstract 
In the 50 years since the first successful human bone marrow transplant (BMT) was performed in 
1959, BMT has become the optimal therapy for a wide variety of life-threatening paediatric 
haematological, immunological and genetic disorders. Unfortunately, while BMT generally provides 
the only possibility of cure for such afflicted children, few (25%) have a matched sibling available, 
and suitably matched unrelated donors are often not identified for many children in need of BMT. 
And even where BMT is possible, treatment is complex and arduous and associated with significant 
mortality and morbidity. The issues raised when either or both the donor and recipient are children 
and lack the capacity to make informed and rational decisions relating to BMT pose great challenges 
for all involved. This paper examines some of the ethical dilemmas that confront patients, families 
and medical practitioners when considering bone marrow transplantation in a child. 
 
Born of the fallout from the most destructive force known to man, bone marrow (BM) 
transplantation (BMT) sits directly on an interesting ethical juncture between harm and cure in 
human history (haematopoietic stem cell transplant, haematopoietic progenitor cell transplantation 
and haematopoietic cellular transplant are all terms used to describe BMT; in this paper, we use the 
term BMT). Despite several early attempts to use transplanted BM therapeutically in the early 
1940s,1 it was not until radiation from the world's first nuclear tests began exposing human subjects 
to severe forms of radiation injury that focus was placed on developing the therapeutic potential of 
BMT.2 Despite extensive backing from the US government, early studies with BMT yielded only very 
limited success and led to the deaths of over 200 patients. It was not until 1959, when the French 
doctor Georges Mathé successfully restored haematopoiesis in six adult Yugoslavian victims of a 
radiation accident that the first partially successful BMT took place.1 BMT became a recognised 
therapy for other forms of BM failure, and in 1968, the world's first successful BM transplant was 
performed on a child with severe combined immunodeficiency syndrome.3 
In the 50 years following Mathé's pioneering work, BMT has become the preferred treatment for a 
diverse range of fatal and debilitating diseases, including BM failure syndromes, 
immunodeficiencies, haematological malignancies, haemoglobinopathies and congenital metabolic 
disorders. 
There are two different types of BMT –autologous BMT and allogeneic BMT. In autologous 
transplantation, the stem cells are collected from and later re-infused into the same individual 
following the administration of high-dose chemotherapy. In allogeneic transplantation, the donor 
and recipient are different individuals. Allogeneic transplantation is further categorised according to: 
2 |  P a g e
 
    The relationship between the donor and the recipient, which can be 
        • syngeneic (identical twin), 
        • related, and 
        • unrelated. 
    The stem cell source: 
        • BM, 
        • umbilical cord blood (CB), and 
        • peripheral blood (PB). 
    The conditioning regimen: 
        • myeloablative (aimed at destroying the recipient's BM) and 
        • non-myeloablative (or reduced intensity conditioning). 
    The degree of immunological (human leukocyte antigen (HLA)) match between donor or recipient: 
        • HLA-matched, 
        • HLA-mismatched, and 
        • haplo-identical (sharing the same haplotype). 
 
In recent years, the number of allogeneic and autologous stem cell transplants world-wide have 
increased dramatically, from less than 1000 (in total) in 1979 to more than 25 000 and 33 000, each 
(respectively), in 2009.4 Of these cases, approximately 25% of the allogeneic transplants and 5% of 
the autologous transplants are performed on children, adolescents and young adults aged less than 
20.4 
BM remains the most common source of stems cells for allogeneic transplantation in children. 
Although the use of PB and umbilical CB is becoming more popular, of the allogeneic transplants 
performed on children between 2004 and 2008, 51% were from BM, 27% were from PB and 22% 
were from umbilical CB. This contrasts rather strikingly with types of grafts most commonly used for 
adults. Of the allogeneic grafts performed on adults between 2004 and 2008, almost 80% of adult 
BMT were from PB, approximately 15% were from BM and the remaining 5% were from CB.4 
At the same time, over the past decade, there has been a substantial increase in CB transplants 
(CBT), particularly in children. This has occurred because CB is easily accessible, has low rates of 
infection and allows transplantation across HLA barriers because of its immunological immaturity 
(enabling transplants for children for whom an unrelated donor may not be easily found (i.e. 
children from ethnic minorities and indigenous populations)). And while early experience with CBT 
demonstrated high rates of graft failure and delayed engraftment (due to the low numbers of 
progenitor cells in the graft), in recent years, outcomes for CBT have significantly improved (in large 
part because of the use of ‘double cord’ transplants, where CB from two individual donors is 
combined) to the extent that in many situations, the outcomes of CBT are equivalent to BMT and PB 
stem cell transplant.5,6 
Key Points 
1. BMT is widely indicated as treatment for a wide range of malignant and nonmalignant 
conditions in children. 
2. Survival rates for BMT are high (>65–70%) but BMT is associated with considerable 
morbidity. 
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3. BMT raises ethical issues relating to; the risks and benefits to the donor and recipient; 
application of new technologies; decision making surrounding BMT, and the cost of BMT. 
 
Indications for Transplantation 
There is a wide range of malignant and non-malignant childhood diseases that can be treated with 
BMT. Some of these diseases (e.g. lymphomas and germ cell tumours) are best treated with 
autologous transplant, while other conditions such as aplastic anaemia, severe combined 
immunodeficiency, leukaemia, thalassaemia, sickle cell disease and inborn errors of metabolism may 
be cured with allogeneic transplant. 
Because the first successful BMT was performed on a child in 1968, there has been dramatic 
progress in transplantation medicine because of advances in tissue typing, improvements in 
supportive care, patient selection, conditioning regimens, the prevention and treatment of graft 
versus host disease, prophylaxis and in the identification of compatible donors via the establishment 
of donor registries and CB banks (there are currently over 450 000 umbilical CB units and 
approximately 15 million people registered with unrelated BM donor registries world-wide).7 For 
many diseases, cure rates following BMT approach 70% in selected patients (Table 1,2). 
 
Table 1.  Bone marrow transplant outcomes.4,8 Survival rates at 5 years post transplant 
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Table 2.  Bone marrow transplant outcomes.4 Causes of death post-BMT 
 
 
Although survival rates for BMT are high for most conditions (approximately 70% in related donor 
transplants and 65% in unrelated donor transplants at 1-year post transplant),4 BMT is associated 
with considerable morbidity, with more than 60% of survivors reporting at least one chronic health 
condition and more than one quarter of survivors experiencing severe or live-threatening 
complications of transplant.9 Additionally, many children experience chronic developmental, 
cognitive and behavioural disorders because of the chemo-radiotherapy they receive during the 
course of BMT (Table 3). 
Table 3.  Bone marrow transplant (BMT) recipient health complications.4,8,10 The long-term 
health complications children face post BMT 
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But while BMT provides the best (and sometimes the only) chance of cure and/or long-term survival 
for many children with life-threatening malignant and non-malignant disorders, BMT also raises a 
series of ethical issues – some of which are shared with other intensive or high-risk therapies, some 
of which are shared with other types of transplantation and some of which are specific to the unique 
circumstances surrounding BMT. 
In general terms, there are five different but intertwined ethical domains that arise in relation to 
BMT in children. These concern 
    • the risks and benefits to the donor, 
    • the risks and benefits to the recipient, 
    • the application of new technologies (i.e. saviour siblings), 
    • the context and structure of the decision-making process itself, and 
    • the socio-economic context surrounding BMT. 
 
Risks and Benefits to the BMT Donor 
While most paediatric transplant physicians believe that stem cell donation is safe in children, 
certain social, psychological and physical risks are apparent. And because there is no medical benefit 
to the child donor for serving as donor, these risks need to be carefully considered. BM harvest, for 
example, requires general anaesthesia and is associated with a number of uncommon complications, 
including nerve, bone and tissue injury.11 Although the risk of death from BM donation is low (less 
than 1 in 10 000 donations),12 this risk is not insignificant in otherwise normal children. BM harvest 
is also associated with a small but significant risk of post-operative morbidity, including pulmonary 
emboli, sickle cell crises, fatigue, localised pain at the donation site, headache, nausea and 
behavioural problems.13 
Although safer than BM harvest, PB stem cell harvest also poses risks to the child, the bulk of which 
relates to the insertion of the large venous catheters necessary for aphaeresis (collection of stem 
cells from the PB). Because of the discomfort and the amount of time aphaeresis takes, many 
children require sedation for the duration of the procedure, resulting in complications in 
approximately 1% of PB donations.14 Apheresis may also cause thrombocytopenia in 5% of 
donors.14 Most significantly, because donors are administered cytokines (granulocyte colony-
stimulating factor (G-CSF)) to encourage the proliferation and release of haematopoietic stem cells 
from the BM into the PB, donors may face both well-recognised short-term and uncertain long-term 
risks related to the administration of G-CSF. The majority of donors who receive G-CSF experience 
fatigue, mild headaches, transient myalgia and arthralgia and rarely, more serious adverse events 
such as splenic pain and rupture.15 While there is no proven association between G-CSF and the 
development of haematological malignancy in normal donors, because concerns have been raised 
about short-term cytogenetic phenomenon in normal donors who have received G-CSF and about 
the potential (although unproven) excess leukaemia in sibling PB stem cell donors, transplant units 
and registries world-wide have a major interest in the long-term follow-up and well-being of their 
donors. 
While the risks of donation may be relatively quantifiable, it is much harder to measure and compare 
the benefits of donation in any meaningful way. While family units may undoubtedly benefit from 
the survival of a loved child or sibling and there is evidence that a donor may obtain a psychological 
benefit from helping someone close,16–18 there is also a growing body of evidence pointing to the 
potential social and psychological harms that donation can cause children.19–23 Donors, for 
example, may feel abandoned when the focus of family attention shifts from them to the recipient 
during the recipient's long recuperation process and/or feel responsible for the outcome of the 
transplant itself.24,25 
6 |  P a g e
 
 
Given that many sibling donors are children, this raises serious questions regarding the degree to 
which sibling donors can consent, or assent, to donation, and the capacity of their parents to fairly 
weigh and to evaluate the risks, benefits and best interests of both their sick and their donor child. 
For these reasons, in countries such as Australia, court approval may be required for a child to 
become a BMT donor for a relative.26 In others, such as the USA, court approval for donation is not 
required for a child to serve as a donor. Instead, voluntary adherence to five key criteria is 
recommended.10 These five criteria specify that: 
1. There must be no medically equivalent histocompatible adult relative who is willing and able 
to donate. 
2. There must be a strong existing (or in the case of CB, anticipated) personal and positive 
relationship between the donor and the recipient. 
3. There must be a reasonable likelihood that the recipient will benefit from the 
transplantation. 
4. Clinical, emotional and psychosocial risks to the donor must be minimised. 
5. Parental permission and donor (the child's) assent must be obtained. 
These criteria are designed to help strike a balance between minimising the psychological, social and 
physical risks to of the donor and maximising the therapeutic outcome of the procedure for the 
recipient. 
 
Risks and Benefits to the BMT Recipient 
As described earlier, BMT is associated with significant short-term and long-term risks to the 
recipient dependent upon the type of disease for which the child is being transplanted, the stage of 
disease at transplant (whether the disease is early or late stage or is in remission or refractory to 
treatment), the relationship between the donor and recipient, the degree of HLA match, and the 
type of conditioning regimen (with mortality, infection rate, graft failure and graft versus host 
disease all more common in unrelated donor and in HLA-mismatched transplants and in children 
with advanced or treatment refractory disease at transplant). 
The majority of children also face significant developmental pathologies following transplant, 
including immunodeficiency, renal disease, infertility, delayed sexual development, growth failure, 
cognitive and behaviour disorders, chronic respiratory failure, avascular necrosis, osteoporosis, 
endocrinopathies, and post-traumatic stress syndrome. As a consequence, survivors of BMT 
continue to require close medical follow-up, something that in itself may disturb return to social 
networks and the transition from childhood into adolescence and adolescence into adulthood.27,28 
The burdens experienced by a child recipient, while expected, create a significant ethical concern. 
This is because, in contrast to a comparable situation facing an adult patient, in children, the 
burdens and benefits of BMT must be evaluated by a competent third party who must then decide 
whether or not to proceed to BMT. In most cases, this task falls squarely upon the shoulders of the 
child's parents. Making a decision in such circumstances is an inordinately difficult task, in part, 
because the parents may feel that they have no choice but to proceed to BMT; in part, because the 
parents' decision-making is predicated upon their love for their child and their concern/fear of losing 
her/him; and in part, because many of the potential complications of BMT are difficult to quantify, 
impossible to predict with any reasonable accuracy and hard even to put into words. For example, 
how can a paediatrician describe, or a parent understand, what it is like for a child to experience 
severe acute graft versus host disease – losing her/his entire skin surface, experiencing continuous 
abdominal pain and nausea and passing litres of diarrhoea each day? When such risks are both 
incomprehensible and incommensurable, children must invariably rely upon their parent's 
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judgement, and their parents, in turn, must place their trust in the care, expertise and prescience of 
the health-care team. 
 
The Application of New Technologies (i.e. Saviour Siblings) 
Until recently, suitably matched donors were often not able to be found for many children who 
lacked a matched related donor – particularly for those from populations under-represented in BM 
registries and CB banks, such as indigenous and Pacific Islander populations and people from the 
Middle East and Indian subcontinent. The combination of in vitro fertilisation (IVF), pre-implantation 
genetic diagnosis, HLA typing of IVF embryos, umbilical CB collection and cryopreservation now 
provides a means for ‘creating’ donors for children who otherwise lack an unrelated donor or a 
suitably matched sibling donor and are awaiting non-urgent transplant (such donors have become 
known in the lay press as ‘saviour siblings’). 
While this may seem an exciting technological fix, as with nearly all medical interventions that are 
associated with human reproduction, strong and often conflicting opinions about just how far we, as 
human beings, should be allowed to influence the development of a human life characterises 
debates about this technology.29 These conflicts tend to obstruct rational debate about the merits 
and dismerits of this approach and generally complicate the vague ethical track that parents and 
clinicians must navigate when deciding just how far they are willing to go to save the life of a child. 
While the notion of using reproductive technologies such as pre-implantation genetic diagnosis with 
HLA typing to identify and select a suitable umbilical CB donor may seem morally challenging, if 
there is little evidence that this process is harmful and it provides benefits to sick children and their 
families (particularly those children that lack a suitable donor because of their ethnicity or HLA type), 
then it is arguable that these technologies should be discussed and even promoted. 
 
The Context and Structure of the Decision-making Process Itself 
While decision-making involving children undergoing BMT is ethically, legally and clinically 
challenging, the process of decision-making becomes notably more complicated where the donor is 
a related to the recipient. The problem is that parents are expected (in law, particularly) to make 
decisions based upon what they believe is in their child's best interests and that these decisions 
should not take into account (or at least be determined by) their own interests or the interests of 
other family members. But, in instances where the donor and recipient are siblings, it may simply 
not be possible to achieve this degree of separation. Indeed, society expects that parents will take 
into account the interests of all of their children and treat them justly and fairly. The specific 
difficulties associated with making decisions in terms of the best interests of the related donors and 
recipients have been recognised world-wide, and it is generally required that donors and recipients 
must be assessed, educated and cared for by different health-care teams and that every effort 
should be made to assist parents make decisions that treat each child as an ‘end in themselves.’10 
 
The Socio-economic Context Surrounding BMT 
The complex treatment regimens, expensive drugs, long hospital stays and long-term follow-up 
required of BMT make it one of the most expensive therapies available as ‘standard therapy’ 
(typically costing hundreds of thousands of dollars). Although there is widespread agreement that 
the expenses for these procedures are well justified (due to the high success rates, and in children 
especially, the high number of quality adjusted life years they will gain), the fact remains that 
funding for BMT places immense strain on even well-funded health systems.30,31 
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Although few would argue that the $200 000–$500 000 cost is not money well spent (especially 
when the life of a child is at stake), the fact remains that in times of fiscal austerity, there is an 
‘opportunity cost’ associated with BMT because the money spent on transplantation is not available 
to be spent on other services that may be required for other children. This poses uncomfortable 
questions about equity of access to medical care and the degree to which the cost of care should 
influence decision-making. Should treatment be given regardless of the cost, for all cases and in all 
situations? Or should we determine a minimum threshold, below which the likelihood of short-term 
‘success’ and the probability of long-term disease-free survival require that treatment be denied? 
There is, of course, no agreed answer to this question, and it is no surprise that disputes around the 
refusal of BMT for children with leukaemia have been central to critiques of attempts to control 
rationally the allocation of health resources in the USA and UK.32,33 
 
Discussion 
Making decisions regarding the treatment of a life-threatening illness is always difficult, even under 
the most supportive conditions and in the most equitable of circumstances. What makes decisions 
about BMT so challenging is the complex social context in which transplant decisions are made, the 
difficulty in predicting outcomes for an individual child and the enormous gulf between good and 
bad outcomes following BMT. Because transplant may provide cure but may also cause awful 
suffering, disability and death, BMT sits in an uncomfortable chasm between probability and chaos. 
And, while few would doubt that all involved in the care of children requiring BMT do their utmost to 
ensure that the child's best interest remain paramount, because these decisions are so urgent and 
characterised by conflicting parental obligations, extremely high financial cost and intractable clinical 
uncertainty, finding the path to a positive outcome, is deceptive and arduous. 
It is cruelly ironic that the genesis of BMT research grew from the unprecedented capacity for 
destruction and harm caused by the atomic bomb. For, in many ways, the history of BMT closely 
parallels the ethical and clinical journey that a child's parents and paediatricians must navigate 
through in a landscape filled with uncertainty and laid bare by the promise of cure and the potential 
for great harm. An ethical dilemma in its purest of forms. 
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